Naoki Hayashi1,2, Yosuke Kuroda1, Tomoko Saito3, Yusuke Tsuruda1,2, Atsushi Niida4, Hajime Otsu1, Hidetoshi Eguchi1, Takaaki Masuda1, Yutaka Suzuki5, Shoji Natsugoe2, Koshi Mimori6. 1. Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu, 874-0838, Japan. 2. Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan. 3. Department of Gastroenterology, Oita University Hospital, 1-1, Idaigaoka, Yufu, 879-5593, Japan. 4. Division of Health Medical Computational Science, Health Intelligence Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. 5. Laboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 5-1-5 Kashiwanoha, Kashiwa-shi, Chiba, 277-8561, Japan. 6. Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu, 874-0838, Japan. kmimori@beppu.kyushu-u.ac.jp.
Abstract
PURPOSE: Recent developments in molecular-targeted therapies have improved the clinical outcome of cancer patients; however, the issue of adverse effects due to treatments has often gone unconsidered. We herein report the results of a clinical trial of dual genomic analyses for healthy longevity in a postoperative cancer patient. METHODS: We performed dual genomic analyses for a representative 79-year-old rectal cancer patient who relapsed with liver metastasis. First, we determined single-nucleotide polymorphisms according to the constitution and disease risk in the genomic DNA from the patient's saliva by referring to the data of 10,000 Japanese patients obtained from Yahoo Japan Corporation. Second, we conducted whole-exome sequencing to detect druggable mutations in the primary tumour. RESULTS: Forty of 59 determinable characters related to the constitution were consistent with the clinical phenotype. Several diseases classified as 'high risk' diseases actually occurred during the patient's clinical course. Of the 129 significant mutations, we identified somatic mutations in BRAF, PIK3CA, and SMAD4 as targets. CONCLUSION: The dual genomic examination will improve the follow-up observation system to support primary care doctors in the social community for taking care of postoperative cancer patients.
PURPOSE: Recent developments in molecular-targeted therapies have improved the clinical outcome of cancerpatients; however, the issue of adverse effects due to treatments has often gone unconsidered. We herein report the results of a clinical trial of dual genomic analyses for healthy longevity in a postoperative cancerpatient. METHODS: We performed dual genomic analyses for a representative 79-year-old rectal cancerpatient who relapsed with liver metastasis. First, we determined single-nucleotide polymorphisms according to the constitution and disease risk in the genomic DNA from the patient's saliva by referring to the data of 10,000 Japanese patients obtained from Yahoo Japan Corporation. Second, we conducted whole-exome sequencing to detect druggable mutations in the primary tumour. RESULTS: Forty of 59 determinable characters related to the constitution were consistent with the clinical phenotype. Several diseases classified as 'high risk' diseases actually occurred during the patient's clinical course. Of the 129 significant mutations, we identified somatic mutations in BRAF, PIK3CA, and SMAD4 as targets. CONCLUSION: The dual genomic examination will improve the follow-up observation system to support primary care doctors in the social community for taking care of postoperative cancerpatients.
Entities:
Keywords:
Disease risk; Healthy longevity; Quality of life; Single nucleotide polymorphism; Somatic mutation
Authors: Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu Journal: Science Date: 2004-03-11 Impact factor: 47.728
Authors: V M Olkkonen; M Johansson; M Suchanek; D Yan; R Hynynen; C Ehnholm; M Jauhiainen; C Thiele; M Lehto Journal: Biochem Soc Trans Date: 2006-06 Impact factor: 5.407
Authors: Nicholas I Fleming; Robert N Jorissen; Dmitri Mouradov; Michael Christie; Anuratha Sakthianandeswaren; Michelle Palmieri; Fiona Day; Shan Li; Cary Tsui; Lara Lipton; Jayesh Desai; Ian T Jones; Stephen McLaughlin; Robyn L Ward; Nicholas J Hawkins; Andrew R Ruszkiewicz; James Moore; Hong-Jian Zhu; John M Mariadason; Antony W Burgess; Dana Busam; Qi Zhao; Robert L Strausberg; Peter Gibbs; Oliver M Sieber Journal: Cancer Res Date: 2012-11-08 Impact factor: 12.701
Authors: Michael S Lawrence; Petar Stojanov; Craig H Mermel; James T Robinson; Levi A Garraway; Todd R Golub; Matthew Meyerson; Stacey B Gabriel; Eric S Lander; Gad Getz Journal: Nature Date: 2014-01-05 Impact factor: 49.962